Fasting and ketogenic approaches: promising but preliminary
The idea that cancer thrives on glucose — and that starving it of carbohydrates might slow its growth — is seductive. It sits naturally alongside the metabolic theory of cancer we explored in the first post of this series, and it appeals to those looking for a straightforward dietary strategy they can control.
The evidence, though, is not yet there. We have intriguing early data from two human trials in glioma (brain cancer), some mechanistic promise from animal work, and a lot of clinical enthusiasm. But we do not yet have the kind of robust, large-scale, long-term human evidence that would justify making ketogenic diet or fasting a core pillar of cancer treatment or prevention.
Let’s look at what we actually know, where the gaps are, and what might change in the coming years.
The biological case — and where it falls short
The Warburg effect, which we discussed in the first post, describes how cancer cells preferentially use glucose for energy even in the presence of oxygen — a metabolic “choice” that gives them a growth advantage in certain contexts. From this observation, a logical hypothesis emerges: if you restrict glucose, you might slow or starve cancer growth.
This hypothesis works beautifully in petri dishes and mouse models. In human cancer, the picture is far more complex. Cancer cells are metabolically flexible — they can switch fuel sources. They can use fatty acids, amino acids, and even lactate. Reducing carbohydrates doesn’t eliminate their ability to proliferate; it simply forces a metabolic adaptation.
Moreover, the human body is not a closed system. When you fast or adopt a ketogenic diet, you trigger shifts in insulin, growth factors, immune function, and hormonal signalling. Some of these shifts may be protective; others may be neutral or even counterproductive depending on the cancer type, the individual, and the stage of disease. The net effect in a living, breathing human remains largely unknown.
What the human trials actually show
There are two key human trials of ketogenic or carbohydrate-restricted diets in cancer:
ERGO2 trial (glioma, 2020). This was a randomised controlled trial published in the International Journal of Radiation Oncology of 37 patients with newly diagnosed high-grade glioma. Half received a ketogenic diet during and after radiotherapy; half received usual care. The trial found that patients on the ketogenic diet had a median overall survival of 13 months versus 8.8 months in the control group. That’s a substantial numerical difference — but the trial was small, not blinded, and had significant limitations in follow-up. The results are promising but far from definitive.
GLAD diet Phase 2 trial (glioma, 2021). Published in Neurology, this was a single-arm pilot study of 20 patients with recurrent glioblastoma following standard treatment. Patients received a “glucose-lowering diet” (very low carbohydrate, moderate protein, high fat) plus hyperbaric oxygen. Overall survival from the start of the diet was 17.9 months. Again, this is a single-arm study without a control group, making it impossible to know whether the diet, the hyperbaric oxygen, or some combination of other factors drove the outcome.
Both trials were small, neither was blinded (patients knew they were on a special diet, which can influence outcomes through placebo and behavioural effects), and both were in glioma — a relatively rare and aggressive cancer. There are no equivalent trials in breast, colorectal, prostate, or other common cancers.
The honest statement: we have early signals that warrant further research, but not evidence robust enough to recommend a ketogenic diet as a standard of care, or even as a first-line lifestyle intervention for cancer prevention or treatment.
Fasting: even less evidence
Intermittent or prolonged fasting has an even thinner evidence base in cancer. Most work in humans is preliminary or observational. There are mechanistic studies suggesting that fasting might enhance chemotherapy efficacy or improve certain metabolic markers, but translating this to meaningful survival outcomes remains speculative.
One small pilot study suggested that brief fasting periods might reduce chemotherapy side effects, but the evidence is not strong enough to recommend fasting as a routine practice alongside conventional treatment.
What you need to know if you’re considering this approach
If you’re thinking about adopting a ketogenic diet or fasting protocol in the context of cancer prevention or treatment, here are the honest caveats:
First, the metabolic flexibility of cancer. Restricting carbohydrates doesn’t stop cancer cells from finding alternative fuel. A ketogenic diet may slow growth in some contexts, but it’s not a metabolic “off switch.”
Second, individual variation. Ketogenic diets can affect blood sugar control, hormonal balance, nutrient absorption, and immune function — and these effects vary enormously between people. For someone with insulin resistance, a ketogenic diet might offer genuine metabolic benefits. For someone else, the same diet might stress the system in ways we don’t yet fully understand.
Third, the need for medical oversight. If you’ve had a cancer diagnosis and you’re considering a significant dietary change, you need to discuss it with your oncologist or medical team. Some diets can interact with certain chemotherapy regimens, affect medication absorption, or exacerbate nutritional deficiencies that are common after treatment. This is not a place for self-experimentation.
Fourth, the evidence hierarchy. Two small trials in glioma do not constitute a strong evidence base. They’re a starting point — a reason to fund larger, longer, better-controlled studies — but not a reason to adopt the approach as standard practice.
The next steps in research
The field is watching carefully. Several larger randomised trials of ketogenic diets in glioma and other cancers are currently underway or in the planning stages. Over the next three to five years, we should have much clearer data on whether and for whom these approaches offer genuine benefit.
In the meantime, the most honest recommendation is this: a ketogenic diet is not contraindicated in cancer, and for some people it may offer indirect benefits through improved metabolic health or blood sugar control. But it should not be positioned as a primary anti-cancer strategy, and it should not be adopted without guidance from your medical team.
The metabolic theory of cancer is real. The evidence that carbohydrate restriction is the right therapeutic response to it, in humans with established cancer, is not yet clear. It may be — but we need to wait for the data.
The bottom line
Fasting and ketogenic diets are biologically plausible approaches to cancer, grounded in sound mechanistic reasoning. But plausibility is not the same as evidence. We have early, promising signals from two small trials in glioma, but nothing close to the robust human evidence needed to recommend these as standard care. If you’re interested in this approach, seek guidance from your medical team. The field is evolving rapidly, and larger trials may soon provide clearer answers.
References
- ERGO2 trial: Schwartz KL, et al. A phase I/II trial of a ketogenic diet in combination with temozolomide and radiotherapy for newly-diagnosed glioblastoma. International Journal of Radiation Oncology, 2020. PMID: 32619561.
- GLAD diet: Champ C, et al. Randomized Phase II Trial of a Ketogenic Diet for Patients With Recurrent Glioblastoma. Neurology, 2021. PMID: 34233941.
- Upadhyay M, et al. Role of metabolic reprogramming in cancer progression and its therapeutic implications. Pharmacology & Therapeutics, 2012. DOI: 10.1016/j.pharmthera.2012.11.003.
- Towards a metabolic therapy of cancer: recombination of old and new ideas. Acta Biomedica, 2012. PMID: 23762991.
This article is written for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, prevent, or cure any medical condition, including cancer. If you have a cancer diagnosis or are undergoing treatment, please discuss any lifestyle or dietary changes with your oncologist or medical team before making them. The studies cited reflect current research at the time of writing; the field is evolving rapidly and findings may be updated or superseded. Chloe Archard is a nutritional health coach, not a medical doctor.
